Neil Kumar

Neil Kumar, the CEO of BridgeBio, shares insights about the company's recent Phase 3 successes and discusses their innovative hub-and-spoke model. He reveals exciting news about the potential full approval for Ripetol and competitive strategies for Atrubi. Meanwhile, STAT reporter Jason Mast dives into Moderna's post-COVID turmoil, examining internal conflicts and the fallout from ambitious expansions. He highlights the challenges ahead for mRNA technology in therapeutics and the impact of political sentiment on the company’s future.